PharmaCyte Biotech Inc (PMCB)

[oldmusky]

Will the following NASDAQ rule come into play with PMCB in 2022? Likely.

"The stock can sell for under $1 a share for 29 consecutive trading days and still be safe from delisting. However, it must sell for $1 or more on day 30."

I said it would take years to complete the FDA's lengthy list associated with PMCB's failed IND.
-We are well into year two, not much has been accomplished.

Completing the list will probably never happen, and provides no Guarantee the IND will ever be lifted.

GENE EDITING is the future of medicine not Snake in a Box.

The good news is PMCB execs will continue to collect huge salaries at share holders expense.

PMCB's five year chart = disaster.

The CEO has no medical background, he is a penny stock lawyer who has a shady past with other companies.

Can the recycled press releases keep this company(?) above a dollar in 2022? I doubt it.